5HTP Regulation Of Asthma In Children: A Double-Blind Placebo Controlled Pilot Study
K
Kirsten Kloepfer, MD
Primary Investigator
Recruiting
8-18 years
All
Phase
2
20 participants needed
3 Locations
Brief description of study
Help IU Researchers learn more about how an over the counter supplement affects asthma and mood.
The purpose of this study is to learn if taking an over the counter supplement called 5-hydroxytryptophan (5HTP) can improve breathing and anxiety symptoms related to asthma. We are seeking children 8-17 years old and young adults 18 years old that have a diagnosis of allergic asthma and appear to be worried or sad about everyday activities
Participants can make up to $150!
Detailed description of study
- Participants will be randomly assigned to take either the supplement (5HTP) or placebo for the first half of the study and switch to the other treatment for the second half of the study.
- Participants will attend 4 study visits over the course of 12 weeks. The visits consist of a physical exam, breathing tests, a blood draw, and a nasal collection test
- Participants could receive up to $150 in gift cards as compensation for participation if they complete each visit ($50 each after Visits 2-4).
If interested contact the study coordinator, Patrick Campbell, at: 317-278-7117 or ptc@iu.edu
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: asthma,children,adults,adult,depression,anxiety, Riley
-
Age: Between 8 Years - 18 Years
-
Gender: All
- Children and adults between 7 and 18 years of age
- Mild to moderate asthma
- Appear to be worried or sad about everyday activities
- Positive allergy test (if no positive allergy test on file, one can be done at Visit 1 to determine eligibility).
- Weigh at least 70 lbs.
- Individuals currently taking an SSRI, biologic medication, or leukotriene inhibitor (e.g. Singulair) will not be eligible.
NOTE: If on a leukotriene inhibitor and you wish to participate, the study doctor can speak to your doctor to determine if it's safe to switch to an alternative medication for the duration of the study.
If interested contact the study coordinator, Patrick Campbell, at: 317-278-7117 or ptc@iu.edu
Updated on
13 Sep 2024.
Study ID: 1902366300, NCT04160910, PPUL-IIR-5HTP
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
